Coya Therapeutics, Inc. Common Stock
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It develops COYA 302, a biologic combination for subcutaneous administration int… Read more
Coya Therapeutics, Inc. Common Stock (COYA) - Total Liabilities
Latest total liabilities as of September 2025: $4.76 Million USD
Based on the latest financial reports, Coya Therapeutics, Inc. Common Stock (COYA) has total liabilities worth $4.76 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Coya Therapeutics, Inc. Common Stock - Total Liabilities Trend (2020–2024)
This chart illustrates how Coya Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Coya Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Coya Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kewal Kiran Clothing Limited
NSE:KKCL
|
India | ₹4.50 Billion |
|
Industri Dan Perdagangan Bintraco Dharma Tbk PT
JK:CARS
|
Indonesia | Rp2.10 Trillion |
|
Genovis AB (publ.)
ST:GENO
|
Sweden | Skr106.41 Million |
|
OPTGF
PINK:OPTGF
|
USA | $148.72 Billion |
|
Indoco Remedies Limited
NSE:INDOCO
|
India | ₹15.34 Billion |
|
Megaforce Co Ltd
TWO:3294
|
Taiwan | NT$2.61 Billion |
|
Keding Enterprises Co Ltd
TW:6655
|
Taiwan | NT$6.22 Billion |
|
Petrolimex Insurance Corp
VN:PGI
|
Vietnam | ₫7.26 Trillion |
Liability Composition Analysis (2020–2024)
This chart breaks down Coya Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Coya Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Coya Therapeutics, Inc. Common Stock (2020–2024)
The table below shows the annual total liabilities of Coya Therapeutics, Inc. Common Stock from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $4.77 Million | -15.23% |
| 2023-12-31 | $5.63 Million | -66.49% |
| 2022-12-31 | $16.79 Million | +1361.98% |
| 2021-12-31 | $1.15 Million | +156.84% |
| 2020-12-31 | $447.12K | -- |